Former FDA commissioner Scott Gottlieb said July 26 that Taylor Farms' decision to contact the White House seeking to delay a recall announcement tied to a cyclospora outbreak was "not standard operating procedure" during his time leading the agency.

Cyclospora is a tiny parasite that makes people sick when it gets into food or water. The illness it causes, called cyclosporiasis, leads to stomach pain, diarrhea, and other uncomfortable symptoms. When the parasite turns up in food, the FDA (the government agency that oversees food safety) works to identify the source and recall the affected products so people stop getting sick.

Speaking on CBS's Face the Nation with host Margaret Brennan, Gottlieb was asked about a Wall Street Journal report that Taylor Farms contacted the Trump White House requesting more time before the government publicly linked the company to the outbreak. According to The Guardian's summary of the WSJ report, the White House then asked FDA officials to join the call with Taylor Farms The Guardian.

"I dealt with outbreaks in romaine lettuce and spinach as well, E coli in spinach and romaine lettuce," Gottlieb said. "I never heard from the White House on those things, other than to have discussions to inform them of what we were doing, so that they were properly briefed and could respond to questions that they were getting" CBS News. He characterized the Taylor Farms situation as "unusual" and said the company's approach was "not standard operating procedure when I was at FDA" either.

The WSJ, which broke the story on July 24, reported that Taylor Farms sought the meeting after executives believed they had not received sufficient clarity from the FDA about the evidence supporting a potential recall and its scope WSJ. During the call, Taylor Farms argued that federal investigators lacked positive laboratory evidence connecting its products to the outbreak and expressed concerns the government was overstating the company's responsibility.

That evidentiary question became more complicated on July 20, when the WSJ reported that the FDA had walked back its earlier finding that a sample of lettuce from Taylor Farms tested positive for cyclospora WSJ. Taylor Farms' recall remained in place. The FDA stated that the false-positive test result does not affect the outbreak conclusions Reuters.

The outbreak itself has been substantial. Cyclospora sickened at least 1,645 people in the U.S. in 2026, according to AP reporting AP News. Michigan alone reported over 6,000 cyclosporiasis cases by July 20 Reuters. The CDC expanded its outbreak investigation to four additional states, the WSJ reported July 24 WSJ.

Taylor Farms, described by the WSJ as a global salad giant, recalled 25 shredded lettuce and salad mix products sold under eight different brand codes, expanding the recall to 27 states AP News. Taco Bell lettuce supplied by Taylor Farms was linked to the outbreak WSJ. Sysco separately pulled iceberg lettuce from central Mexico linked to the U.S. cyclosporiasis outbreak Reuters.

The broader context here is about how food safety is supposed to work, and what happens when that process gets disrupted. Normally, when the FDA suspects a company's food is making people sick, the agency works directly with that company to share evidence and arrange a recall. Think of it like a referee calling a foul: the referee explains the call, and the team accepts it. In this case, Taylor Farms disagreed with the call and went over the referee's head to someone with more authority, the White House. Gottlieb's comments suggest that kind of escalation was not how things worked when he ran the FDA. At the same time, the FDA's retraction of its positive test result adds some weight to Taylor Farms' complaint that the evidence against them was not airtight. Yet the recall held, and the outbreak conclusions stood.

The tension between those two facts, a retracted lab finding and a sustained recall, is where the policy stakes concentrate. If the FDA's broader investigation can hold up without the lab confirmation it initially claimed, that speaks to the strength of how investigators piece together outbreaks by looking at patterns of illness rather than relying on a single test. But it also means a company's argument that investigators overstated their evidence can be partly true and still not be enough to change the outcome. For food-industry compliance professionals and public-health officials, the episode is a case study in how disagreements over evidence during an active outbreak can move from a technical dispute to a political one, and in what the norms are, or were, when they do.